IOVAIOVANCE BIOTHERAPEUTICS, INC.

Nasdaq iovance.com


$ 9.94 $ 1.98 (24.94 %)    

Friday, 09-Aug-2024 15:59:57 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 9.92
$ 9.92 x 300
-- x --
-- - --
$ 3.21 - $ 18.33
23,625,123
na
2.83B
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-05-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-04-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 08-03-2017 06-30-2017 10-Q
30 05-03-2017 03-31-2017 10-Q
31 03-09-2017 12-31-2016 10-K
32 11-04-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-11-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 skin-cancer-focused-iovance-biotherapeutics-reports-better-than-expected-2024-2025-outlook-stock-surges

Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations.

Core News & Articles
Market-Moving News for August 9th
08/09/2024 12:16:31

KITT: 79% | Nauticus Robotics Partners With Florida Atlantic University For Cost-Effective Aquanaut Mark 2 Testing IOVA: 38% | ...

 iovance-biotherapeutics-q2-2024-adj-eps-034-beats-035-estimate-sales-3111m-beat-2459m-estimate

Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate ...

 iovance-biotherapeutics-price-forecast-slashed-by-40-on-mutated-uptake-for-its-newly-approved-skin-cancer-cell-therapy

Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite...

 piper-sandler-downgrades-iovance-biotherapeutics-to-neutral-lowers-price-target-to-10

Piper Sandler analyst Joseph Catanzaro downgrades Iovance Biotherapeutics (NASDAQ:IOVA) from Overweight to Neutral and lower...

 viasat--ast-spacemobile-are-among-top-6-mid-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 jmp-securities-maintains-market-outperform-on-iovance-biotherapeutics-lowers-price-target-to-23

JMP Securities analyst Reni Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and lowers the...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

 hc-wainwright--co-reiterates-buy-on-iovance-biotherapeutics-maintains-32-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION